Aspirin and Cancer

详细信息    查看全文

• 作者：Paola Patrignani ; PhD^a ; Carlo Patrono ; MD^b ; ^{carlo.patrono@rm.unicatt.it" class="auth_mail" title="E-mail the corresponding author}
• 关键词：chemoprevention ; colorectal neoplasms ; cyclooxygenase-1 ; nonsteroidal anti-inflammatory agents ; platelet activation ; prostaglandins
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：30 August 2016
• 年：2016
• 卷：68
• 期：9
• 页码：967-976
• 全文大小：1195 K

文摘

The place of aspirin in primary prevention remains controversial, with North American and European organizations issuing contradictory treatment guidelines. More recently, the U.S. Preventive Services Task Force recommended “initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.” This recommendation reflects increasing evidence for a chemopreventive effect of low-dose aspirin against colorectal (and other) cancer. The intent of this paper is to review the evidence supporting a chemopreventive effect of aspirin, discuss its potential mechanism(s) of action, and provide a conceptual framework for assessing current guidelines in the light of ongoing studies.